SDC1 and cancer: A cytoplasmic CD138 positivity was earlier recorded in 59% of 103 cancers [25], 64% of 60 cancers [20], 50% of 5 metastatic cancers [15], 32% of 42 hormone-refractory cancers [15], and 47% of 196 localized cancers [15].